- Press Releases archive
- < Recipharm Monts secures regulatory approval from ANSM to fill biotech products
Recipharm Monts secures regulatory approval from ANSM to fill biotech products
17 September 2012
Site set to expand its sterile product service offering.
Recipharm Monts, located near Tours (France), specialist in the manufacture of sterile products in glass containers, today announced it has secured authorisation from the French health authorities (ANSM) to fill biotech products. Consequently, Recipharm is able to expand and diversify its combined offering.
The Monts site, which employs 200 personnel, comprises three filling lines. Two large capacity lines are used for glass vials for injection and a third one is an aseptic line that fills cartridges.
The timing of the new authorisation coincides with the site installing a new, highly flexible vials line with multiple formats designed to handle smaller capacity orders. The first production on this line, designed to fill both clinical and small commercial batches, will be readily available to the life science and pharmaceuticals market from mid 2013 onwards.
Michel Saudemon, General Manager at Recipharm Monts, commented: “We are delighted to have the opportunity to expand our sterile product manufacturing services with the authorised capability to fill biotech products.”
He added: “This regulatory approval, coming at a time when we have already set in place a programme of strategic expansion at the Monts site with the installation of a new service line, will serve to increase the range of sterile product manufacturing services that we can offer to the markets.”
Notes to editors
Recipharm AB is a leading contract development and manufacturing organization (CDMO) based in Sweden employing some 1700 employees. The Company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with hundreds of different products in multiple dosage forms that include solid dose, granulates and powders, sterile liquids and lyophilisates, semi solids, beta-lactams, hormones, oral liquids, sprays and dry powder inhalers. For more information visit: www.recipharm.com
Recipharm – Michel Saudemon, General Manager, +33 2 47 21 10 59
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on:
E-mail: email@example.com or firstname.lastname@example.org
Tel: +44 (0) 207 861 3019/3043